Organogenesis Holdings Stock Performance
| ORGO Stock | USD 4.97 0.04 0.80% |
Organogenesis Holdings holds a performance score of 6 on a scale of zero to a hundred. The company holds a Beta of 5.09, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Organogenesis Holdings will likely underperform. Use Organogenesis Holdings downside variance, and the relationship between the sortino ratio and accumulation distribution , to analyze future returns on Organogenesis Holdings.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Organogenesis Holdings are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent technical and fundamental indicators, Organogenesis Holdings displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.80) | Five Day Return (6.23) | Year To Date Return 64.03 | Ten Year Return (49.03) | All Time Return (49.03) |
1 | Disposition of 5585 shares by Gillheeney Gary S. of Organogenesis Holdings at 3.49 subject to Rule 16b-3 | 12/16/2024 |
2 | Disposition of 500000 shares by Gn 2016 Family Trust Uad August 12, 2016 of Organogenesis Holdings at 4.057 subject to Rule 16b-3 | 12/27/2024 |
3 | Acquisition by Ades Alan A. of 6401945 shares of Organogenesis Holdings subject to Rule 16b-3 | 01/08/2025 |
4 | Disposition of 3643 shares by Freedman Lori of Organogenesis Holdings at 3.68 subject to Rule 16b-3 | 01/17/2025 |
5 | Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on ... | 01/27/2025 |
6 | Disposition of 17972 shares by Erani Albert of Organogenesis Holdings at 4.2775 subject to Rule 16b-3 | 01/28/2025 |
7 | Disposition of 804 shares by David Francisco of Organogenesis Holdings at 3.7 subject to Rule 16b-3 | 02/14/2025 |
8 | Acquisition by Driscoll Michael Joseph of 49575 shares of Organogenesis Holdings subject to Rule 16b-3 | 02/19/2025 |
9 | What To Expect From Organogenesis Holdings Inc Q4 2024 Earnings | 02/26/2025 |
10 | Organogenesis Holdings Inc Q4 2024 Earnings EPS of 0. ... | 02/27/2025 |
11 | Q4 2024 Organogenesis Holdings Inc Earnings Call Transcript | 02/28/2025 |
12 | Disposition of 25000 shares by Driscoll Michael Joseph of Organogenesis Holdings at 5.1014 subject to Rule 16b-3 | 03/04/2025 |
13 | Organogenesis Shares Down 6.2 percent Heres What Happened | 03/05/2025 |
14 | Insider Sell Michael Driscoll Sells 25,000 Shares of Organogenesis Holdings Inc | 03/07/2025 |
15 | Disposition of 8657 shares by Montecalvo Antonio S. of Organogenesis Holdings at 3.7 subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 104.3 M | |
| Free Cash Flow | 4.2 M |
Organogenesis |
Organogenesis Holdings Relative Risk vs. Return Landscape
If you would invest 357.00 in Organogenesis Holdings on December 17, 2024 and sell it today you would earn a total of 144.00 from holding Organogenesis Holdings or generate 40.34% return on investment over 90 days. Organogenesis Holdings is currently generating 1.2106% in daily expected returns and assumes 14.1269% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Organogenesis, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Organogenesis Holdings Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Organogenesis Holdings' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Organogenesis Holdings, and traders can use it to determine the average amount a Organogenesis Holdings' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0857
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ORGO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 14.13 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.21 actual daily | 24 76% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Organogenesis Holdings is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Organogenesis Holdings by adding it to a well-diversified portfolio.
Organogenesis Holdings Fundamentals Growth
Organogenesis Stock prices reflect investors' perceptions of the future prospects and financial health of Organogenesis Holdings, and Organogenesis Holdings fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Organogenesis Stock performance.
| Return On Equity | 0.0026 | ||||
| Return On Asset | 0.0281 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 664.93 M | ||||
| Shares Outstanding | 126.83 M | ||||
| Price To Earning | 17.12 X | ||||
| Price To Book | 2.41 X | ||||
| Price To Sales | 1.32 X | ||||
| Revenue | 482.04 M | ||||
| Gross Profit | 366.3 M | ||||
| EBITDA | (1.28 M) | ||||
| Net Income | 861 K | ||||
| Cash And Equivalents | 113.24 M | ||||
| Cash Per Share | 0.87 X | ||||
| Total Debt | 43.31 M | ||||
| Debt To Equity | 0.52 % | ||||
| Current Ratio | 2.62 X | ||||
| Book Value Per Share | 2.09 X | ||||
| Cash Flow From Operations | 14.21 M | ||||
| Earnings Per Share | (0.01) X | ||||
| Market Capitalization | 635.41 M | ||||
| Total Asset | 497.89 M | ||||
| Retained Earnings | (40.11 M) | ||||
| Working Capital | 208.46 M | ||||
| Current Asset | 24.47 M | ||||
| Current Liabilities | 23.22 M | ||||
About Organogenesis Holdings Performance
By examining Organogenesis Holdings' fundamental ratios, stakeholders can obtain critical insights into Organogenesis Holdings' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Organogenesis Holdings is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 82.68 | 100.99 |
Things to note about Organogenesis Holdings performance evaluation
Checking the ongoing alerts about Organogenesis Holdings for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Organogenesis Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Organogenesis Holdings is way too risky over 90 days horizon | |
| Organogenesis Holdings appears to be risky and price may revert if volatility continues | |
| Organogenesis Holdings has a strong financial position based on the latest SEC filings | |
| About 47.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Insider Sell Michael Driscoll Sells 25,000 Shares of Organogenesis Holdings Inc |
- Analyzing Organogenesis Holdings' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Organogenesis Holdings' stock is overvalued or undervalued compared to its peers.
- Examining Organogenesis Holdings' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Organogenesis Holdings' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Organogenesis Holdings' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Organogenesis Holdings' stock. These opinions can provide insight into Organogenesis Holdings' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.5 | Earnings Share (0.01) | Revenue Per Share | Quarterly Revenue Growth 0.271 | Return On Assets |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.